Tau proteins have been proposed as candidate markers of stroke and SDNG for evaluating the extent of neurodegeneration, and potentially discriminating neuronal damage with the presence of degenerative processes of other etiology, such as Alzheimer’s pathology. This evidence concerns the gene MAPT and Stroke.